Breast Cancer
Conditions
Brief summary
This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the therapy ER+/HER2- recurrent metastatic breast cancer。
Interventions
DRUGnab-paclitaxel
nab-paclitaxel 125mg / m2, intravenous drip 30min, d1, 8, 21 days as a cycle, until the disease progresses or intolerable toxicity. According to the calculation results, the administered dose can be within ± 10% of the calculated dose.
Sponsors
Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Female, 18 to 70 years old; 2. histologically confirmed recurrent or metastatic breast cancer, ER-positive (\> 10%), HER-2 negative (Definition: immunohistochemical \[IHC\] 0, 1+, or in situ hybridization \[ISH\] negative It is defined as the ratio of HER2 gene copy number to the number of CEP17 signals is less than 2.0, or for single probe detection, the HER2 gene copy number is less than 6); 3. After transfer, ≤2 lines and ≥1 line endocrine therapy, and progress; 4. at least one measurable lesion according to RECIST 1.1 ; 5. ECOG score≤2; 6. Expected survival≥3 months; 7. Bone marrow function: white blood cells≥3×109/L, neutrophils≥1.5×109/L, platelets ≥100×109 / L, hemoglobin≥90g / L; 8. Liver and kidney function: total bilirubin (TBIL) ≤1.5 times the upper limit of normal value, alanine aminotransferase (ALT), aspartate aminotransferase (AST) are ≤2.5 times the upper limit of normal value; if due to liver metastasis, the above indicators ≤5 times the upper limit of normal value; serum creatinine (Cr) ≤1.5 times the upper limit of normal value; 9. taxane adjuvant chemotherapy for more than 1 year; 10. Women of childbearing age have a negative pregnancy test and must agree to take effective contraceptive measures during the study and within 3 months after the last dose 11. Sign written informed consent before the test.
Exclusion criteria
1. Received chemotherapy after transfer; 2. Patients with congestive heart failure with a grade II or above identified by the New York Heart Association (NYHA) score; 3. Uncontrolled brain metastases; 4. Severe systemic infections; 5. Peripheral neuropathy of degree II or above within 4 weeks before enrollment, or patients known to be allergic or intolerant to this drug; 6. Important organ diseases:liver and kidney dysfunction, history of myocardial infarction, unstable heart disease, chronic active hepatitis, etc .; 7. History of other malignant tumors within 5 years (except cured cervical cancer or skin basal cell carcinoma); 8. Received other anti-tumor treatments or other experimental drugs within 1 month before starting treatment; 9. Patients participating in other clinical trials at the same time; 10. Any medical condition in which the investigator considers the patient unsuitable for study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Estimated up to 1 year | Defined as proportion of complete response and partial response according to RECIST 1.1 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical benefit rate | CR+PR+SD≥8 weeks | Defined as proportion of complete response 、partial response and stable disease according to RECIST 1.1 criteria. |
| Progression-Free Survival (PFS) | Estimated up to 2 year | Calculated from the time the study drug was first administered to the first confirmation of disease progression or death (whichever occurs first) |
Contacts
Primary ContactPeng Yuan
Outcome results
None listed